Moderna, Novavax Hit 52-Week Lows

Seeking Alpha2022-09-29

The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.

Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), Ocugen (OCGN), and Inovio Pharmaceuticals (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.

Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.

MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and Enterprise Expansion, effective Jan. 01.

“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.

Dr. Jerh Collins, who headed Head of Global Chemical Operations at Novartis (NVS), will succeed Mr. Andres.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Seah CL
2022-09-29
Seah CL
K
andrew123
2022-09-29
andrew123
Omg
MINH
2022-09-29
MINH
Noted
Singmeamelodyy
2022-09-29
Singmeamelodyy
O
KSR
2022-09-29
KSR
Great thoughts.
Stingray8
2022-09-29
Stingray8
Game over 😅

Leave a comment

115

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199226004?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2022-09-29 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199226004","market":"us","top_or_hot":-1,"title":"Moderna, Novavax Hit 52-Week Lows","media":"Seeking Alpha","content":"<html><head></head><body><p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NASDAQ:NVAX) reaching 52-week lows.<img src=\"https://static.tigerbbs.com/f39bba4d2f0635ea35262903a7358152\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"/></p><p>Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> (OCGN), and <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.</p><p>Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.</p><p>MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and <a href=\"https://laohu8.com/S/EBTC\">Enterprise</a> Expansion, effective Jan. 01.</p><p>“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.</p><p>Dr. Jerh Collins, who headed Head of Global <a href=\"https://laohu8.com/S/TCFCP\">Chemical</a> Operations at Novartis (NVS), will succeed Mr. Andres.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Novavax Hit 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Novavax Hit 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-29 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge","article_id":"1199226004","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199226004","pubTimestamp":1664463766,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (N","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"诺瓦瓦克斯莫德纳创下52周低点","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"NVAX":0.9},"content_text":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), Ocugen (OCGN), and Inovio Pharmaceuticals (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and Enterprise Expansion, effective Jan. 01.“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.Dr. Jerh Collins, who headed Head of Global Chemical Operations at Novartis (NVS), will succeed Mr. Andres.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[{"id":9916045256,"gmtCreate":1664493661575,"gmtModify":1676537463844,"author":{"id":"4102135564535180","authorId":"4102135564535180","name":"Seah CL","avatar":"https://community-static.tradeup.com/news/970bca7b04e85a42a2c8eabed7ec96d0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4102135564535180","authorIdStr":"4102135564535180"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9916045256","repostId":1199226004,"repostType":4,"repost":{"id":"1199226004","kind":"news","pubTimestamp":1664463766,"share":"https://ttm.financial/m/news/1199226004?lang=&edition=full_marsco","pubTime":"2022-09-29 23:02","market":"us","language":"en","title":"Moderna, Novavax Hit 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=1199226004","media":"Seeking Alpha","summary":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (N","content":"<html><head></head><body><p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NASDAQ:NVAX) reaching 52-week lows.<img src=\"https://static.tigerbbs.com/f39bba4d2f0635ea35262903a7358152\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"/></p><p>Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> (OCGN), and <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.</p><p>Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.</p><p>MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and <a href=\"https://laohu8.com/S/EBTC\">Enterprise</a> Expansion, effective Jan. 01.</p><p>“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.</p><p>Dr. Jerh Collins, who headed Head of Global <a href=\"https://laohu8.com/S/TCFCP\">Chemical</a> Operations at Novartis (NVS), will succeed Mr. Andres.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Novavax Hit 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Novavax Hit 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-29 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199226004","content_text":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), Ocugen (OCGN), and Inovio Pharmaceuticals (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and Enterprise Expansion, effective Jan. 01.“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.Dr. Jerh Collins, who headed Head of Global Chemical Operations at Novartis (NVS), will succeed Mr. Andres.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9916051066,"gmtCreate":1664492310355,"gmtModify":1676537463381,"author":{"id":"3576260758860416","authorId":"3576260758860416","name":"andrew123","avatar":"https://community-static.tradeup.com/news/f2a1eaba26272212d42018e60e78b422","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":4,"crmLevelSwitch":0,"idStr":"3576260758860416","authorIdStr":"3576260758860416"},"htmlText":"Omg","listText":"Omg","text":"Omg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9916051066","repostId":1199226004,"repostType":4,"repost":{"id":"1199226004","kind":"news","pubTimestamp":1664463766,"share":"https://ttm.financial/m/news/1199226004?lang=&edition=full_marsco","pubTime":"2022-09-29 23:02","market":"us","language":"en","title":"Moderna, Novavax Hit 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=1199226004","media":"Seeking Alpha","summary":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (N","content":"<html><head></head><body><p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NASDAQ:NVAX) reaching 52-week lows.<img src=\"https://static.tigerbbs.com/f39bba4d2f0635ea35262903a7358152\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"/></p><p>Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> (OCGN), and <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.</p><p>Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.</p><p>MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and <a href=\"https://laohu8.com/S/EBTC\">Enterprise</a> Expansion, effective Jan. 01.</p><p>“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.</p><p>Dr. Jerh Collins, who headed Head of Global <a href=\"https://laohu8.com/S/TCFCP\">Chemical</a> Operations at Novartis (NVS), will succeed Mr. Andres.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Novavax Hit 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Novavax Hit 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-29 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199226004","content_text":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), Ocugen (OCGN), and Inovio Pharmaceuticals (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and Enterprise Expansion, effective Jan. 01.“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.Dr. Jerh Collins, who headed Head of Global Chemical Operations at Novartis (NVS), will succeed Mr. Andres.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9916013036,"gmtCreate":1664486600425,"gmtModify":1676537462129,"author":{"id":"3586859788675252","authorId":"3586859788675252","name":"MINH","avatar":"https://static.tigerbbs.com/536eb7671d76bffcba14ebf4ccd21b93","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586859788675252","authorIdStr":"3586859788675252"},"htmlText":"Noted&nbsp;","listText":"Noted&nbsp;","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9916013036","repostId":1199226004,"repostType":4,"repost":{"id":"1199226004","kind":"news","pubTimestamp":1664463766,"share":"https://ttm.financial/m/news/1199226004?lang=&edition=full_marsco","pubTime":"2022-09-29 23:02","market":"us","language":"en","title":"Moderna, Novavax Hit 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=1199226004","media":"Seeking Alpha","summary":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (N","content":"<html><head></head><body><p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NASDAQ:NVAX) reaching 52-week lows.<img src=\"https://static.tigerbbs.com/f39bba4d2f0635ea35262903a7358152\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"/></p><p>Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> (OCGN), and <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.</p><p>Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.</p><p>MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and <a href=\"https://laohu8.com/S/EBTC\">Enterprise</a> Expansion, effective Jan. 01.</p><p>“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.</p><p>Dr. Jerh Collins, who headed Head of Global <a href=\"https://laohu8.com/S/TCFCP\">Chemical</a> Operations at Novartis (NVS), will succeed Mr. Andres.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Novavax Hit 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Novavax Hit 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-29 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199226004","content_text":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), Ocugen (OCGN), and Inovio Pharmaceuticals (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and Enterprise Expansion, effective Jan. 01.“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.Dr. Jerh Collins, who headed Head of Global Chemical Operations at Novartis (NVS), will succeed Mr. Andres.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9916035014,"gmtCreate":1664480339138,"gmtModify":1676537461949,"author":{"id":"4112236528991632","authorId":"4112236528991632","name":"Singmeamelodyy","avatar":"https://community-static.tradeup.com/news/bd6f4b2042c573a893dce45a93a107fb","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4112236528991632","authorIdStr":"4112236528991632"},"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9916035014","repostId":1199226004,"repostType":4,"repost":{"id":"1199226004","kind":"news","pubTimestamp":1664463766,"share":"https://ttm.financial/m/news/1199226004?lang=&edition=full_marsco","pubTime":"2022-09-29 23:02","market":"us","language":"en","title":"Moderna, Novavax Hit 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=1199226004","media":"Seeking Alpha","summary":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (N","content":"<html><head></head><body><p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NASDAQ:NVAX) reaching 52-week lows.<img src=\"https://static.tigerbbs.com/f39bba4d2f0635ea35262903a7358152\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"/></p><p>Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> (OCGN), and <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.</p><p>Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.</p><p>MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and <a href=\"https://laohu8.com/S/EBTC\">Enterprise</a> Expansion, effective Jan. 01.</p><p>“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.</p><p>Dr. Jerh Collins, who headed Head of Global <a href=\"https://laohu8.com/S/TCFCP\">Chemical</a> Operations at Novartis (NVS), will succeed Mr. Andres.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Novavax Hit 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Novavax Hit 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-29 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199226004","content_text":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), Ocugen (OCGN), and Inovio Pharmaceuticals (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and Enterprise Expansion, effective Jan. 01.“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.Dr. Jerh Collins, who headed Head of Global Chemical Operations at Novartis (NVS), will succeed Mr. Andres.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9916099230,"gmtCreate":1664467725720,"gmtModify":1676537461296,"author":{"id":"4121076730674632","authorId":"4121076730674632","name":"KSR","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4121076730674632","authorIdStr":"4121076730674632"},"htmlText":"Great thoughts.","listText":"Great thoughts.","text":"Great thoughts.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9916099230","repostId":1199226004,"repostType":4,"repost":{"id":"1199226004","kind":"news","pubTimestamp":1664463766,"share":"https://ttm.financial/m/news/1199226004?lang=&edition=full_marsco","pubTime":"2022-09-29 23:02","market":"us","language":"en","title":"Moderna, Novavax Hit 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=1199226004","media":"Seeking Alpha","summary":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (N","content":"<html><head></head><body><p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NASDAQ:NVAX) reaching 52-week lows.<img src=\"https://static.tigerbbs.com/f39bba4d2f0635ea35262903a7358152\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"/></p><p>Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> (OCGN), and <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.</p><p>Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.</p><p>MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and <a href=\"https://laohu8.com/S/EBTC\">Enterprise</a> Expansion, effective Jan. 01.</p><p>“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.</p><p>Dr. Jerh Collins, who headed Head of Global <a href=\"https://laohu8.com/S/TCFCP\">Chemical</a> Operations at Novartis (NVS), will succeed Mr. Andres.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Novavax Hit 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Novavax Hit 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-29 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199226004","content_text":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), Ocugen (OCGN), and Inovio Pharmaceuticals (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and Enterprise Expansion, effective Jan. 01.“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.Dr. Jerh Collins, who headed Head of Global Chemical Operations at Novartis (NVS), will succeed Mr. Andres.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9916009295,"gmtCreate":1664465585317,"gmtModify":1676537460925,"author":{"id":"3582101468174801","authorId":"3582101468174801","name":"Stingray8","avatar":"https://community-static.tradeup.com/news/61835c24442db698417e83348c394372","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3582101468174801","authorIdStr":"3582101468174801"},"htmlText":"Game over 😅","listText":"Game over 😅","text":"Game over 😅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9916009295","repostId":1199226004,"repostType":4,"repost":{"id":"1199226004","kind":"news","pubTimestamp":1664463766,"share":"https://ttm.financial/m/news/1199226004?lang=&edition=full_marsco","pubTime":"2022-09-29 23:02","market":"us","language":"en","title":"Moderna, Novavax Hit 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=1199226004","media":"Seeking Alpha","summary":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (N","content":"<html><head></head><body><p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NASDAQ:NVAX) reaching 52-week lows.<img src=\"https://static.tigerbbs.com/f39bba4d2f0635ea35262903a7358152\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"/></p><p>Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> (OCGN), and <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.</p><p>Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.</p><p>MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and <a href=\"https://laohu8.com/S/EBTC\">Enterprise</a> Expansion, effective Jan. 01.</p><p>“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.</p><p>Dr. Jerh Collins, who headed Head of Global <a href=\"https://laohu8.com/S/TCFCP\">Chemical</a> Operations at Novartis (NVS), will succeed Mr. Andres.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Novavax Hit 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Novavax Hit 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-29 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3887181-mrna-stock-nvax-stock-ocgn-stock-plunge","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199226004","content_text":"The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine development, Valneva (VALN), Vaxart (VXRT), Ocugen (OCGN), and Inovio Pharmaceuticals (INO), have also joined the selloff, which coincided with a market-wide weakness in stocks.Moderna (MRNA) is trading at levels not seen since January 2021, and Novavax (NVAX) has approached the lowest level since May 2020.MRNA announced Thursday that Juan Andres, its Chief Technical Operations and Quality Officer, will take up a new role as President, Strategic Partnerships and Enterprise Expansion, effective Jan. 01.“In his new role, Mr. Andres will focus on building out the Company’s organization to support its growing pipeline,” MRNA added.Dr. Jerh Collins, who headed Head of Global Chemical Operations at Novartis (NVS), will succeed Mr. Andres.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":115,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.34.0","shortVersion":"4.34.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199226004"}